1. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (10th December 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (9th November 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Issue 26 (10th September 2021) Authors: Diab, Adi; Tykodi, Scott S.; Daniels, Gregory A.; Maio, Michele; Curti, Brendan D.; Lewis, Karl D.; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander I.; Cho, Daniel C.; Guan, Shanhong; Puente, Erika; Nguyen, Tuan; Hoch, Ute; Currie, Sue L.; Lin, Wei; Tagliaferri, Mary A.; Zalevsky, Jon... Journal: Journal of clinical oncology Issue: Volume 39:Issue 26(2021) Page Start: 2914 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma. Issue 1 (6th November 2019) Authors: Herrera, Alex F.; Goy, Andre; Mehta, Amitkumar; Ramchandren, Radhakrishnan; Pagel, John M.; Svoboda, Jakub; Guan, Shanhong; Hill, John S.; Kwei, Kevin; Liu, Emily A.; Phillips, Tycel Journal: American journal of hematology Issue: Volume 95:Issue 1(2020:Jan.) Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗